Literature DB >> 12837970

Pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis.

Yutaka Terata1, Takashi Saito, Yoshimasa Fujiwara, Hitoshi Hasegawa, Hiroto Miura, Hiroyuki Watanabe, Yoshikatsu Chiba, Satoshi Kibira, Mamoru Miura.   

Abstract

UNLABELLED: We have reported that intermediate conductance Ca(2+)-activated K(+) channels (ImK) showed augmented expression in angiotensin II (AII) type 1 receptor-dependent manner in post-ischemic rat heart. ImK has tyrosine phosphorylation sequence in the C-terminus and motifs for NFkappaB and AP1 in the promoter. While statin inhibits AII-mediated vascular remodeling via anti-inflammatory effect independent of cholesterol lowering. To test the possible effect of statin on expression of ImK, Wistar-Kyoto rats received L-nitro-arginine methyl ester (LNAME: 1 mg/ml in drinking water) for 4 weeks in group L. While in L+P group, rats received both LNAME and pitavastatin (PTV: 1 mg/kg/day in drinking water). Temporal profile of ImK mRNA was examined by RT-PCR using specific primers for ImK.
RESULTS: Long-term LNAME administration produced significant hypertension and resulted in marked microvascular remodeling characterized by medial thickening and perivascular fibrosis of coronary arterioles (100-200 microm in diameter). RT-PCR revealed significant up-regulation of ImK mRNA with two distinct peaks in L group in the early phase (days 3-7) and the late phase (4 weeks). PTV partially inhibited a rise in systolic blood pressure, but completely abolished the first peak of ImK upregulation (0.76 +/- 0.04 vs. 3.96 +/- 1.43 folds at day 7, p < 0.001). Co-treatments with PTV also significantly inhibited medial thickening and perivascular fibrosis. These findings indicate that statin inhibits microvascular remodeling induced by chronic inhibition of NO synthesis through the action independent of cholesterol lowering. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12837970     DOI: 10.1159/000070455

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  10 in total

1.  KCa 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS.

Authors:  Serge Simonet; Marc Isabelle; Mélanie Bousquenaud; Nicolas Clavreul; Michel Félétou; Christine Vayssettes-Courchay; Tony J Verbeuren
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 2.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

3.  Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin.

Authors:  Masaki Kitahara; Tatsuro Kanaki; Itsuko Ishii; Yasushi Saito
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

4.  The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling.

Authors:  Dan Bi; Kazuyoshi Toyama; Vincent Lemaître; Jun Takai; Fan Fan; David P Jenkins; Heike Wulff; David D Gutterman; Frank Park; Hiroto Miura
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

5.  The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.

Authors:  Kazuyoshi Toyama; Heike Wulff; K George Chandy; Philippe Azam; Girija Raman; Takashi Saito; Yoshimasa Fujiwara; David L Mattson; Satarupa Das; James E Melvin; Phillip F Pratt; Ossama A Hatoum; David D Gutterman; David R Harder; Hiroto Miura
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

6.  Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells.

Authors:  S W Seto; A L S Au; T Y Lam; S S C Chim; S M Y Lee; S Wan; D C S Tjiu; N Shigemura; A P C Yim; S W Chan; S K W Tsui; G P H Leung; Y W Kwan
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

7.  Acute simvastatin inhibits K ATP channels of porcine coronary artery myocytes.

Authors:  Sai Wang Seto; Alice Lai Shan Au; Christina Chui Wa Poon; Qian Zhang; Rachel Wai Sum Li; John Hok Keung Yeung; Siu Kai Kong; Sai Ming Ngai; Song Wan; Ho Pui Ho; Simon Ming Yuen Lee; Maggie Pui Man Hoi; Shun Wan Chan; George Pak Heng Leung; Yiu Wa Kwan
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

8.  Spectrophotometric Determination of Cefetamet Pivoxil Hydrochloride and Pitavastatin Calcium in Tablet Dosage form.

Authors:  N H Vadia; Vandana Patel; H N Bhalara
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

9.  Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.

Authors:  Masatoki Yoshida; Kazufumi Nakamura; Toru Miyoshi; Masashi Yoshida; Megumi Kondo; Kaoru Akazawa; Tomonari Kimura; Hiroaki Ohtsuka; Yuko Ohno; Daiji Miura; Hiroshi Ito
Journal:  Cardiovasc Diabetol       Date:  2020-09-26       Impact factor: 9.951

10.  Enhancement of the Solubility and Bioavailability of Pitavastatin through a Self-Nanoemulsifying Drug Delivery System (SNEDDS).

Authors:  Mehran Ashfaq; Shahid Shah; Akhtar Rasul; Muhammad Hanif; Hafeez Ullah Khan; Ahmed Khames; Mohamed A Abdelgawad; Mohammed M Ghoneim; Muhammad Yasir Ali; Mohammad A S Abourehab; Safirah Maheen; Omeira Iqbal; Ghulam Abbas; Amani M El Sisi
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.